GlassScriptPhysician profile
Tayler Renea Yoder
NPI 1720699986
$8,456.01
in general payments reported to CMS, 2019-2025
29 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,703 · 2022: $2,194 · 2023: $1,489 · 2024: $1,747 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.44 |
| Education | $281.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $984.66 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $966.82 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $965.94 | 2021-2025 | |
| Galderma Laboratories, L.P. | $803.94 | 2021-2025 | Aklief, Oracea, Epsolay |
| Regeneron Healthcare Solutions, INC. | $759.70 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $743.75 | 2021-2025 | |
| Lilly USA, LLC | $502.84 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $384.71 | 2021-2025 | Jublia, Cabtreo, Duobrii |
| Sun Pharmaceutical Industries INC. | $375.49 | 2021-2025 | |
| Pfizer INC. | $359.86 | 2021-2025 | |
| Amgen INC. | $343.92 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $292.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.48 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $137.03 | 2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $83.53 | 2024-2025 | Bimzelx |
| Incyte Corporation | $73.87 | 2023-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Mayne Pharma Commercial LLC | $55.82 | 2022-2024 | |
| Epi Health, LLC | $53.68 | 2021-2022 | |
| Leo Pharma INC. | $51.01 | 2025 | Adbry, Spevigo |
| Verrica Pharmaceuticals INC. | $39.06 | 2023-2024 | Ycanth |
| Organon LLC | $18.80 | 2025 | Vtama |
| Therapeuticsmd, INC. | $17.92 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.35 | 2024 | Zoryve |
| Almirall LLC | $16.49 | 2021 | |
| Strata Skin Sciences, INC. | $14.50 | 2025 | Xtrac |
| Dermira, INC. | $13.78 | 2021 | |
| Allergan, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayler Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.